Early prediction of survival to gefitinib or chemotherapy using integrated FDG-PET for patients with advanced non-small cell lung cancer

Early prediction of survival to gefitinib or chemotherapy using integrated FDG-PET for patients with advanced non-small cell lung cancer - PET trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006682

Enrollment

Registered

2011-11-08

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

PET examination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The main eligibility criterion was pathologically confirmed stage IIIB or IV NSCLC. Additional criteria were as follows: (1) Eastern Cooperative Oncology Group performance status from 0 to 2, (2) bidimensionally measurable lesion(s) on FDG-PET and CT scans, (3) no prior chemotherapy or prior molecular-targeted therapy.

Exclusion criteria

Exclusion criteria: The patients with uncontrolled diabetes mellitus, defined as fasting blood glucose higher than 150 mg/dl, were excluded.

Design outcomes

Primary

Measure	Time frame
FDG-PET was performed before and 3 day after initiation of each treatment. Based on previous studies, a reduction of tumor FDG uptake was assessed by using standardized uptake value (SUV).	—

Countries

Japan

Contacts

Public ContactMasaki Kanazu

Kinki-chuo Chest Medical Center Internal Medicine

kanamasa@kch.hosp.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026